Menu
Back to Journals » OncoTargets and Therapy » Volume 6
Novel Bruton's tyrosine kinase inhibitors currently in development
Received 19 December 2012
Accepted for publication 4 February 2013
Published 6 March 2013 Volume 2013:6 Pages 161—176
DOI https://doi.org/10.2147/OTT.S33732
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Osmond J D'Cruz,1 Fatih M Uckun1,2
1Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; 2Department of Pediatrics, University of Southern California, Los Angeles, CA, USA
Abstract: Bruton's tyrosine kinase (Btk) is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells. Btk is overexpressed and constitutively active in several B-lineage lymphoid malignancies. Btk has emerged as a new antiapoptotic molecular target for treatment of B-lineage leukemias and lymphomas. Preclinical and early clinical results indicate that Btk inhibitors may be useful in the treatment of leukemias and lymphomas.
Keywords: tyrosine kinase, personalized therapy, kinase inhibitors, Btk, leukemia, lymphoma
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.